文献速递类风湿关节炎

靶向类风湿关节炎滑膜成纤维细胞增殖:TRAFIC 开放标签剂量探索1b期试验

Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial.
PubMed 文献 · Lancet Rheumatol · 2021-03-09

BACKGROUND: Current rheumatoid arthritis therapies target immune inflammation and are subject to ceiling effects. Seliciclib is an orally available cyclin-dependent kinase inhibitor that suppresses proliferation of synovial fibroblasts-cells not yet targeted in rheumatoid arthrit…

要点

  • seliciclib在抗TNF难治性RA中的最大耐受剂量为400 mg。
  • 发生剂量限制性毒性者平均Cmax与AUC0-6为未发生者的两倍。

核心结论

  • seliciclib在抗TNF阻断难治的类风湿关节炎中已确定最大耐受剂量,未发现阻碍正式疗效试验的意外安全性问题。

研究设计与样本

  • TRAFIC 1b期为非随机、开放标签、剂量探索试验,在英国5家国民健康服务体系医院风湿科开展。
  • 纳入年龄≥18岁、符合1987年ACR或2010年ACR-EULAR分类标准、DAS28≥3·2且入组前抗TNF治疗稳定至少3个月的患者。
  • 序贯入组最多7个队列、每队列3例,seliciclib以200 mg口服胶囊给予200、400、600、800或1000 mg。
  • 剂量由限制性一阶段贝叶斯持续再评估模型决定,以目标剂量限制性毒性率35%确定最大耐受剂量(主要结局)。
  • 2015年10月8日至2017年8月15日筛查37例,15例入组5个队列并接受seliciclib。

主要发现

  • 15例入组患者中10例(67%)除TNF抑制剂外还使用传统合成改善病情抗风湿药。
  • seliciclib最大耐受剂量为400 mg,剂量限制性毒性概率估计0·35(90%后验概率区间0·18–0·52)。
  • 发生2例严重不良事件:600 mg剂量组1例急性肾损伤、400 mg剂量组1例药物性肝损伤,均认为与seliciclib相关且符合其已知安全性特征。
  • 试验期间发生65例非严重不良事件,其中50例认为与治疗相关,大多数治疗相关不良事件为轻度,20例治疗相关非严重不良事件构成剂量限制性毒性。
  • 发生剂量限制性毒性者的平均Cmax与AUC0-6为未发生者的两倍,无死亡。

关键数值与推荐

  • 最大耐受剂量定义为基于目标剂量限制性毒性率35%由贝叶斯持续再评估模型确定的剂量。
  • seliciclib最大耐受剂量为400 mg,剂量限制性毒性概率估计0·35(90%后验概率区间0·18–0·52)。
  • 入组要求DAS28≥3·2且抗TNF治疗稳定至少3个月。

临床怎么用

  • 对抗TNF治疗难治的类风湿关节炎,seliciclib 400 mg为1b期确定的进一步疗效试验用剂量。
  • 用药监测需关注急性肾损伤与药物性肝损伤等已知安全性信号。

局限性

  • 本研究为非随机、开放标签、小样本剂量探索1b期试验,仅15例入组,未评估疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current rheumatoid arthritis therapies target immune inflammation and are subject to ceiling effects. Seliciclib is an orally available cyclin-dependent kinase inhibitor that suppresses proliferation of synovial fibroblasts-cells not yet targeted in rheumatoid arthritis. Part 1 of this phase 1b/2a trial aimed to establish the maximum tolerated dose of seliciclib in patients with active rheumatoid arthritis despite ongoing treatment with TNF inhibitors, and to evaluate safety and pharmacokinetics. METHODS: Phase 1b of the TRAFIC study was a non-randomised, open-label, dose-finding trial done in rheumatology departments in five UK National Health Service hospitals. Eligible patients (aged ≥18 years) fulfilled the 1987 American College of Rheumatology (ACR) or the 2010 ACR-European League Against Rheumatism classification criteria for rheumatoid arthritis and had moderate to severe disease activity (a Disease Activity Score for 28 joints [DAS28] of ≥3·2) despite stable treatment with anti-TNF therapy for at least 3 months before enrolment. Participants were recruited sequentially to a maximum of seven cohorts of three participants each, designated to receive seliciclib 200 mg, 400 mg, 600 mg, 800 mg, or 1000 mg administered in 200 mg oral capsules. Sequential cohorts received doses determined by a restricted, one-stage Bayesian continual reassessment model, which determined the maximum tolerated dose (the primary outcome) based on a target dose-limiting toxicity rate of 35%. Seliciclib maximum concentration (Cmax) and area under the plasma concentration time curve 0-6 h (AUC0-6) were measured. This study is registered with ISRCTN, ISRCTN36667085. FINDINGS: Between Oct 8, 2015, and Aug 15, 2017, 37 patients were screened and 15 were enrolled to five cohorts and received seliciclib, after which the trial steering committee and the data monitoring committee determined that the maximum tolerated dose could be defined. In addition to a TNF inhibitor, ten (67%) enrolled patients were taking conventional synthetic disease modifying antirheumatic drugs. The maximum tolerated dose of seliciclib was 400 mg, with an estimated dose-limiting toxicity probability of 0·35 (90% posterior probability interval 0·18-0·52). Two serious adverse events occurred (one acute kidney injury in a patient receiving the 600 mg dose and one drug-induced liver injury in a patient receiving the 400 mg dose), both considered to be related to seliciclib and consistent with its known safety profile. 65 non-serious adverse events occurred during the trial, 50 of which were considered to be treatment related. Most treatment-related adverse events were mild; 20 of the treatment-related non-serious adverse events contributed to dose-limiting toxicities. There were no deaths. Average Cmax and AUC0-6 were two-times higher in participants developing dose-limiting toxicities. INTERPRETATION: The maximum tolerated dose of seliciclib has been defined for rheumatoid arthritis refractory to TNF blockade. No unexpected safety concerns were identified to preclude ongoing clinical evaluation in a formal efficacy trial. FUNDING: UK Medical Research Council, Cyclacel, Research into Inflammatory Arthritis Centre (Versus Arthritis), and the National Institute of Health Research Newcastle and Birmingham Biomedical Research Centres and Clinical Research Facilities.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Pratt AG, Siebert S, Cole M, et al. Targeting synovial fibroblast proliferation in rheumatoid arthritis (TRAFIC): an open-label, dose-finding, phase 1b trial. Lancet Rheumatol. 2021. PMID: 33928262. doi:10.1016/S2665-9913(21)00061-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。